Bone Biologics

Bone Biologics EPS

The Earnings per Share (EPS) of Bone Biologics (BBLG) as of Oct 27, 2026 is -2.65 USD. In the previous year, Earnings per Share (EPS) was -1.39 USD — a change of 90.10% (lower).

EPS

-2.65USD

YoY

90.10%

Last updated:

Earnings per Share (EPS) of Bone Biologics is 2025 -2.65 USD. Earnings per Share (EPS) of Bone Biologics was 2024 -1.39 USD. It decreases by 90.10% lower compared to the previous year.

The Bone Biologics EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2020
-0.06 USD
Jan 1, 2021
-37.37 USD
Jan 1, 2022
-23.27 USD
Jan 1, 2023
-19.50 USD
Jan 1, 2024
-1.39 USD
Jan 1, 2025
-2.65 USD
Jan 1, 2026 (e)
-1.23 USD
Jan 1, 2027 (e)
-0.67 USD
The Bone Biologics EPS history
YEAREPSYoY
est-0.67USD-45.53%
est-1.23USD-53.52%
-2.65USD+90.10%
-1.39USD-92.86%
-19.50USD-16.21%
-23.27USD-37.73%
-37.37USD+62,740.03%
-0.06USD-99.91%
-67.02USD-88.96%
-606.85USD+33,096.00%
-1.83USD-99.95%
-3,981.38USD+1,130.82%
-323.47USD+93,458.63%
-0.35USD+59.77%
-0.22USD+151,228.67%
-0.00USD-94.64%
-0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bone Biologics Stock analysis

What does Bone Biologics do? Bone Biologics Corp. generates revenue through the development and sale of its NELL-1/DBM Fusion Device, a bone regeneration product for spinal fusion procedures. The device combines NELL-1, a recombinant human protein, with demineralized bone matrix (DBM) to provide targeted bone regeneration control. Medical professionals use the product for spine implants, non-union trauma cases, and osteoporosis treatments. The company's platform technology, centered on NELL-1, is developed through laboratory and animal research to support applications in bone void filling and skeletal regeneration. The firm focuses on osteopromotive applications using NELL-1, a skeletal-specific growth factor proven in laboratory models to replicate human growth and development. NELL-1 is marketed as a bone void filler and is integrated into spinal fusion devices. The company's revenue streams derive from the commercialization of NELL-1-based products targeting orthopedic and spinal surgery markets. Medical device companies and healthcare providers purchase the NELL-1/DBM Fusion Device for clinical use in bone regeneration procedures. Bone Biologics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bone Biologics stock

Earnings per Share (EPS) of Bone Biologics is -2.65 USD in 2025.

Earnings per Share (EPS) of Bone Biologics changed from -1.39 USD to -2.65 USD, representing a 90.10% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Bone Biologics since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Bone Biologics

All Key Metrics — Bone Biologics